A $1.5 billion all-stock acquisition will combine advanced MRD technology with a leading AI oncology platform, expanding access to cancer monitoring and accelerating innovation in the $20 billion MRD market. Closing is expected by early 2027, pending approvals.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.